Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan

Cell Death and Differentiation

Volumn 7, Issue 11, 2000, Pages 1127-1136

  Dejosez M ^a   Ramp, U ^a   Mahotka, C ^a   Krieg, A ^a   Walczak, H ^b   Gabbert, H E ^a   Gerharz, C D ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Apoptosis; Renal cell carcinoma; Topoisomerase I inhibitor; Topotecan; TRAIL

Indexed keywords

DNA TOPOISOMERASE INHIBITOR; IMMUNOGLOBULIN FC FRAGMENT; LIGAND; MEMBRANE PROTEIN; NEUTRALIZING ANTIBODY; PROTEIN P53; TOPOTECAN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL DEATH; CONTROLLED STUDY; DRUG POTENTIATION; GENE MUTATION; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION;

EID: 0033710429     PISSN: 13509047     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cdd.4400746     Document Type: Article

References (56)

1. Renal cell carcinomas: Treatment with recombinant interleukin-2 plus beta-interferon
2. Continuous infusion of recombinant interleukin-2 with or without autologous activated killer cells for the treatment of advanced renal cell carcinoma
3. Mechanisms and modulation of multidrug-resistance in primary human renal cell carcinoma
4. Expression of HLA-A,B,C antigens on primary and metastasic tumor cell populations of human carcinomas
5. Identification of human cancers deficient in antigen processing
6. Acquisition of TGF-β1 resistance: An important progression factor in human renal cell carcinoma
7. To die or not to die. An overview of apoptosis and its role in disease
8. Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells
9. Deficient activation of the CD95(APO-1/Fas) system in drug-resistant cells
10. The CD95(APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells
11. Drug-induced apoptosis in hepatoma cells is mediated by the CD95(APO-1/Fas) system and involves activation of wild-type p53
12. KILLER/DR5 is a DNA damage inducible p53-regulated death receptor gene
13. p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha
14. Identification and characterization of a new member of the TNF family that induces apoptosis
15. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family
16. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors
17. How TRAIL kills cancer cells, but not normal cells
18. TRAIL-R2: A novel apoptosis mediating receptor for TRAIL
19. Safety and antitumor activity of recombinant soluble Apo2 ligand
20. TRAIL: A molecule with multiple receptors and control mechanisms
21. To die or not to die - The quest of the TRAIL receptors
22. The receptor for the cytotoxic ligand TRAIL
23. An antagonist decoy receptor and a death domain-containing receptor for TRAIL
24. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family
25. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL
26. Lymphocyte inhibitor of TRAIL (TNF-related apoptosis-inducing ligand): A new receptor protecting lymphocytes from the death ligand TRAIL
27. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain
28. A novel receptor for Apo2L/TRAIL contains a truncated death domain
29. TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signaling
30. The CD95 (APO-1/Fas) and the TRAIL apoptosis systems
31. Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing Ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of Type 1 IFNs
32. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo
33. Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK and F104864), a new camptothecin analogue
34. TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL
35. Genomic organization and mutation analyses of the DR5/TRAIL receptor 2 gene in colorectal carcinomas
36. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells
37. TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in FAS ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells
38. Topotecan - A novel topoisomerase I-Inhibitor: Pharmacology and clinical experience
39. Clinical implications of the p53 tumor-suppressor gene
40. Chromosome 17p deletions and p53 mutations in renal cell carcinoma
41. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia
42. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway
43. Characterization of two receptors for TRAIL
44. Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies
45. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines
46. Apoptosis signaling by death receptors
47. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand expressing tumor cells - A mechanism of immune evasion?
48. The tumor strikes back. New data on expression of the CD95 (APO-1/Fas) receptor/ligand system may cause paradigm changes in our view on drug treatment and tumor immunology
49. Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11
50. Ultrastructural appearance and cytoskeletal architecture of the clear, chromophilic, and chromophobe types of human renal carcinoma in vitro
51. Establishment and characterization of two divergent cell lines derived from a human chromophobe renal cell carcinoma
52. Chromophilic renal cell carcinoma: Cytomorphological and cytogenetic characterisation of four permanent cell lines
53. Resistance to CD95 (APO-1/Fas)-mediated apoptosis in human renal cell carcinomas: An important factor for evasion from negative growth control
54. Survivin-ΔEx3 and survivin-2B: Two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties
55. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxity assays
56. Effects of more than one inhibitor